A New Drug Application, or NDA, is the formal request a pharmaceutical company submits to the FDA asking for permission to sell a new drug in the United States. It contains every piece of evidence the company has gathered about the drug’s safety, effectiveness, and manufacturing quality, often spanning hundreds of thousands of pages. No prescription drug can reach the U.S. market without one.
The NDA is the culmination of years of research and clinical trials. It represents the point where a drug company says: here is everything we know about this product, and we believe it proves the drug works and is safe enough to prescribe.
What an NDA Actually Contains
NDAs follow an internationally standardized format called the Common Technical Document, which organizes everything into five modules. The first module covers administrative details and proposed prescribing information, including the label doctors and pharmacists will reference. The second provides summaries of everything else in the application, giving FDA reviewers an accessible overview before they dive into the raw data.
Module 3 is the quality section, covering chemistry, manufacturing, and controls. This is where the company proves it can reliably produce the drug to consistent standards. It includes details on the drug’s chemical identity, purity, strength, and stability over time, along with a full description of manufacturing processes, facility conditions, and quality testing methods. The FDA needs to know that every batch of the drug will be the same as the batches used in clinical trials.
Module 4 contains all nonclinical (animal) studies, covering the drug’s pharmacological effects, toxicity profile, and any reproductive or fetal risks observed in lab testing. Module 5 is typically the largest section: full clinical study reports from every human trial conducted, from early dose-finding studies through the large Phase 3 trials that establish whether the drug actually works.
Two Types of NDAs
Not all NDAs are the same. A standard NDA, filed under section 505(b)(1) of federal law, relies entirely on the company’s own research or studies it has licensed the rights to use. This is the path for genuinely novel drugs where the company ran or sponsored every study in the application.
A 505(b)(2) application is a hybrid. It still qualifies as an NDA, but at least some of the safety and effectiveness data comes from studies the applicant didn’t conduct and doesn’t have a license to reference. This pathway is common for drugs that build on existing knowledge, like a new formulation of an already-approved drug, a new dosage form, or a new combination of known ingredients. It lets companies avoid repeating studies that have already been done, which saves time and money while still requiring new evidence where gaps exist.
How the FDA Reviews an NDA
Once the FDA receives an NDA, it has 60 days to decide whether the application is complete enough to file for review. If something essential is missing, the agency can refuse to file it, sending it back before the clock even starts.
Applications that pass this initial check get assigned to a multidisciplinary review team. Medical officers evaluate all clinical trial data, looking at study design, endpoints, and whether the results genuinely support the drug’s proposed use. Pharmacology and toxicology specialists assess the animal studies, focusing on the drug’s mechanism of action and potential for toxic effects. Statisticians independently analyze the clinical trial data, checking whether the company’s conclusions hold up. Chemists and microbiologists review the manufacturing evidence. Clinical pharmacology reviewers evaluate how the drug is absorbed, distributed through the body, metabolized, and eliminated.
A project manager coordinates this entire team, serving as the primary contact with the drug company and keeping the review on schedule.
How Long the Review Takes
The FDA commits to specific review timelines under a framework called the Prescription Drug User Fee Act (PDUFA). For standard reviews, the agency aims to act on 90% of applications within 10 months. Drugs that qualify for priority review, typically those offering significant improvements over existing treatments, get a faster timeline of 6 months.
These timelines begin from the filing date for new molecular entities (entirely new drugs) and from the receipt date for other NDAs. “Acting on” an application doesn’t necessarily mean approving it. The FDA may approve, request more information, or issue a rejection.
What It Costs to File
Filing an NDA is expensive. For fiscal year 2025, the application fee for an NDA requiring clinical data is $4,310,002. Applications that don’t require clinical data cost $2,155,001. On top of that, approved drug companies pay an annual program fee of $403,889. These user fees fund the FDA’s review operations and are a major reason the agency can maintain its review timelines. Waivers and reductions exist for qualifying circumstances, and companies can submit written requests for fee relief within 180 days of when a fee is due.
What Happens if the FDA Says No
When the FDA finds problems with an NDA, it issues a Complete Response Letter rather than an outright denial. This letter details exactly what deficiencies need to be addressed before the drug can be approved. The most common reasons include safety and efficacy concerns (the data doesn’t convincingly show the drug works or its risks outweigh its benefits), manufacturing deficiencies (the company can’t demonstrate consistent, quality production), and bioequivalence issues (the drug’s behavior in the body doesn’t match what’s expected).
A Complete Response Letter isn’t the end of the road. Companies can address the problems and resubmit. Some drugs take multiple rounds before earning approval, while others never make it through.
NDA vs. BLA
Not every therapeutic product goes through the NDA pathway. Biological products, which include vaccines, blood products, gene therapies, and most antibody-based treatments, require a Biologics License Application (BLA) instead. BLAs are governed by the Public Health Service Act rather than the Food, Drug, and Cosmetic Act, though the review process is similar. The key distinction is the type of product: traditional chemical drugs go through NDAs, while complex products derived from living sources go through BLAs.
What Happens After Approval
An NDA approval doesn’t end the company’s obligations. The FDA can require postmarketing studies and clinical trials to gather additional information about a drug’s safety, effectiveness, or optimal use after it reaches patients. These postmarketing requirements became significantly more robust after the 2007 FDA Amendments Act, which gave the agency authority to mandate studies that assess known serious risks, investigate signals of serious risk that emerge from real-world use, or identify unexpected serious risks when available data suggest something concerning.
The FDA can also require companies to conduct pediatric studies, run confirmatory trials for drugs approved under the accelerated approval pathway, and complete human safety studies for products initially approved based on animal data alone. Companies must regularly report on the status of these commitments, and failure to comply can result in enforcement action.